Becton, Dickinson and Company (BDX) Income Statement

The reported revenue decline appears driven by the divestiture of the diabetes care business, which distorts organic comparisons. Excluding this, underlying growth may be modest, but the sequential improvement from 2026Q2 to 2026Q3 suggests stabilization. Investors should monitor whether the 'New BD' can reaccelerate growth through its higher-margin interventional and life sciences segments.

The sequential gross margin improvement suggests that BDX is effectively managing raw material costs, likely through pricing actions and a favorable product mix shift toward higher-margin interventional and diagnostic products. However, the gross margin remains below peers like Boston Scientific (69%) and Medtronic (65%), reflecting BDX's heavier exposure to lower-margin consumables. Sustained expansion will depend on the success of connected device and molecular diagnostics initiatives.

The dramatic operating margin fluctuation in 2026Q2 appears tied to restructuring or impairment charges, as evidenced by the net loss and zero SBC. Excluding these one-offs, the underlying operating margin trend is more stable, hovering around 11-13% in recent quarters. This suggests that BDX's high fixed-cost base can amplify earnings swings, but the company is not yet demonstrating consistent operating leverage as revenue growth remains subdued.

The reduction in R&D spending as a percentage of revenue (from 6.0% in 2026Q1 to 5.2% in 2026Q3) may indicate a deliberate focus on near-term profitability, but it could also signal a slowdown in innovation investment. SG&A has been relatively stable, suggesting that BDX is not aggressively cutting overhead despite revenue contraction. This mixed cost discipline may limit margin expansion potential in the near term.